Last reviewed · How we verify
NT0102
NT0102 is a prodrug formulation of methylphenidate designed to provide extended-release delivery with reduced abuse potential.
NT0102 is a prodrug formulation of methylphenidate designed to provide extended-release delivery with reduced abuse potential. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
At a glance
| Generic name | NT0102 |
|---|---|
| Sponsor | Neos Therapeutics, Inc |
| Drug class | Psychostimulant (methylphenidate prodrug) |
| Target | Dopamine transporter (DAT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
NT0102 utilizes Neos Therapeutics' proprietary technology to deliver methylphenidate in a controlled manner that aims to minimize peak plasma concentrations and reduce the drug's potential for misuse. The formulation is engineered to provide therapeutic benefit for ADHD while maintaining a lower abuse liability profile compared to immediate-release methylphenidate formulations.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
Common side effects
- Decreased appetite
- Insomnia
- Headache
- Abdominal pain
- Anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |